Pharmaceutical composition effective in preventing the adverse effects associated with the prolonged use of dihydrofolate reductase inhibitors

1. A tablet or capsule, consisting essentially of:

a. a reduced form of folate selected from the group consisting of 5-methyltetrahydrofolate, folinic acid, and pharmaceutically acceptable salts thereof;

b. milk thistle standarized extract;

c. at least one B complex vitamin; and

d. at least one amino acid selected from the group consisting of L-methionine, DL-methionine, S-adenosyl-L-methionine, S-adenosyl-L-methionine tosylate disulfate, L-serine, DL-serine, phosphatidyl serine, and L-glycine, DL-glycine, timethyl glycine.

2. The tablet or capsule of claim 1 , wherein the reduced form of folate is 5-methyltetrahydrofolate.

3. The tablet or capsule of claim 1 , wherein the milk thistle extract is a standardized extract to 80% silymarin.

4. The tablet or capsule of claim 1 , wherein the B complex vitamin is selected from the group consisting of vitamin B12, vitamin B6, and vitamin B2.

5. The tablet or capsule of claim 4 , wherein the vitamin B12 is selected from the group consisting of methylcobalamin, cyanocobalamin, and hydroxycobalamin; the vitamin B6 is selected from the group consisting of pyridoxine, pyridoxal 5′phosphate, pyridoxamine, and pyridoxine hydrochloride; and the vitamin B2 is riboflavin.

6. The tablet or capsule of claim 4 , wherein the vitamin B12 is methylcobalamin; the vitamin B6 is pyridoxine hydrochloride; and the vitamin B2 is riboflavin.

7. A tablet or capsule, consisting essentially of:

a. Folate, in an amount between 200.0 μg and 5.0 mg;

b. Milk thistle extract, in an amount between 40.0 mg and 400.0 mg;

c. Vitamin B12 as methylcobalamin, in an amount between 6.0 μg and 1,000.0 μg;

d. Vitamin B6 as pyridoxine hydrochloride, in an amount between 2.0 mg and 100.0 mg;

e. Vitamin B2 as riboflavin, in an amount between 1.7 mg and 100.0 mg;

f. L-Methionine, in an amount between 25.0 mg and 400.0 mg;

g. L-Serine, in an amount between 25.0 mg and 400.0 mg; and

h. L-Glycine, in an amount between 25.0 mg and 400.0 mg.

8. A tablet or capsule, consisting essentially of:

a. Folate, in an amount of 800.0 μg and 2.0 mg;

b. Milk thistle extract, in an amount between 75.0 mg and 200.0 mg;

c. Vitamin B12 as methylcobalamin, in an amount between 25.0 μg and 100.0 μg;

d. Vitamin B6 as pyridoxine hydrochloride, in an amount between 5.0 mg and 50.0 mg;

e. Vitamin B2 as riboflavin, in an amount between 2.5 mg and 50.0 mg;

f. L-Methionine, in an amount between 50.0 mg and 250.0 mg;

g. L-Serine, in an amount between 50.0 mg and 250.0 mg; and

h. L-Glycine, in an amount between 50.0 mg and 250.0 mg.

9. A tablet or capsule, consisting essentially of:

a. at least one of 5-methyltetrahydrofolate, folinic acid, and pharmaceutically acceptable salts thereof;

b. milk thistle standarized extract;

c. at least one of vitamins B2, B6, and B12; and

d. at least one of L-methionine, L-serine, and L-glycine.

10. A method of treatment to prevent adverse effects associated with the long term use of dihydrofolate reductase inhibitors, comprising:

a) administering the composition of claim 1 to a patient, wherein a first dose of the composition of claim 1 is administered at least 48 hours after the administration of a single dose course of methotrexate; or

b) administering the composition of claim 1 to a patient, wherein a first dose of the composition of claim 1 is administered at least 30 hours after the administration of a third dose of a three dose course of methotrexate.

11. The method of claim 10 , wherein five doses of the composition of claim 1 are administered to the patient.

12. The method of claim 10 , wherein the composition of claim 1 is administered orally.

13. The method of claim 10 , wherein the single dose of methotrexate or the three dose course of methothrexate are part of a weekly regiment.

14. A method of using the composition according to claim 1 , comprising:

administering a pharmaceutical dosage form of the composition of claim 1 orally to a patient subject to treatment with dihydrofolate reductase inhibitors selected from the group consisting of Methotrexate, Pemetrexed, Trimethoprim and Pyrimethamine.